PTC Therapeutics, a biopharmaceutical firm, is making strides in developing and bringing novel drugs to market for those suffering from obscure ailments. The company boasts a wide-ranging pipeline, including multiple therapies in different development phases targeting rare diseases. Their current offerings in the market include Translarna and Emflaza, aimed at treating Duchenne muscular dystrophy, and Tegsedi, Waylivra, and Evrysdi for a variety of rare diseases. PTC's innovative platforms include splicing, gene therapy, oncology, and metabolics. The company partners with other leading pharmaceutical firms to further develop breakthrough treatments, including F. Hoffman-La Roche and Akcea Therapeutics. PTC Therapeutics was founded in 1998 and has its headquarters located in South Plainfield, New Jersey.